Back to Top
research biosimilars
-
-
February 01, 2024
Antibody therapeutics have made significant strides in recent years, with several successful treatments already in the market. However, the future of this field lies in the promising candidates currently in Phase I-II clinical trials. These antibodies, targeting a wide range of diseases, have the potential to become important treatments in the coming years.
One such antibody is DSP-0038, a humanized monoclonal antibody targeting the TROP2...
